Uphill Task: Can We Ever Conquer Against New Emerging Viruses?

JMS SKIMS ◽  
2017 ◽  
Vol 20 (2) ◽  
pp. 109-110
Author(s):  
Farooq A Sheikh

Every time there is a major infectious disease outbreak that scares us, such as Ebola in West Africa, Middle East Respiratory Syndrome (MERS) on the Arabian Peninsula and South Africa, and Zika virus in South and Central America and the Caribbean; this time arising from a mosquito-borne agent that has spread stealth around the globe [ 1]. It remains one of the great mysteries of the Zika epidemic: Why did a virus that existed for decades elsewhere in the world suddenly seem to become more destructive when it landed in Latin America? An intriguing study in mice, which has prompted some skepticism among experts, suggests that a single genetic mutation- called S139N, first arose in an Asian strain of the Zika virus in 2013, just before a small outbreak in French Polynesia, helped transform the Zika virus into a devastating force in Latin America [2 ]. JMS 2017;20(2):115-116

2017 ◽  
Vol 11 (11) ◽  
pp. e0006007 ◽  
Author(s):  
Felipe J. Colón-González ◽  
Carlos A. Peres ◽  
Christine Steiner São Bernardo ◽  
Paul R. Hunter ◽  
Iain R. Lake

mSphere ◽  
2018 ◽  
Vol 3 (1) ◽  
Author(s):  
Albert To ◽  
Liana O. Medina ◽  
Kenji O. Mfuh ◽  
Michael M. Lieberman ◽  
Teri Ann S. Wong ◽  
...  

The recent outbreaks of Zika virus (ZIKV) infection in French Polynesia, the Caribbean, and the Americas have highlighted the severe neuropathological sequelae that such an infection may cause. The development of a safe, effective ZIKV vaccine is critical for several reasons: (i) the difficulty in diagnosing an active infection due to common nonspecific symptoms, (ii) the lack of a specific antiviral therapy, and (iii) the potentially devastating pathological effects ofin uteroinfection. Moreover, a vaccine with an excellent safety profile, such as a nonreplicating, noninfectious vaccine, would be ideal for high-risk people (e.g., pregnant women, immunocompromised patients, and elderly individuals). This report describes the development of a recombinant subunit protein vaccine candidate derived from stably transformed insect cells expressing the ZIKV envelope proteinin vitro, the primary antigen to which effective virus-neutralizing antibodies are engendered by immunized animals for several other flaviviruses; the vaccine candidate elicits effective virus-neutralizing antibodies against ZIKV and provides protection against ZIKV infection in mice.


2019 ◽  
Author(s):  
Alasdair D Henderson ◽  
Maite Aubry ◽  
Mike Kama ◽  
Jessica Vanhomwegen ◽  
Anita Teissier ◽  
...  

SUMMARYBackgroundSerosurveys published following major outbreaks of Zika virus (ZIKV) have so far shown a high level of seroprevalence from samples collected within 12 months of the first confirmed case. A common assumption is that ZIKV infection confers long-term protection against reinfection, preventing ZIKV from re-emerging in previously affected areas for many years. However, the long-term immune response to ZIKV following an outbreak remains poorly documented.MethodsWe compared results from eight serological surveys, with sample sizes ranging from 49 to 700, before and after known ZIKV outbreaks in the Pacific region: five from cross-sectional studies of schoolchildren and the general population in French Polynesia over a seven-year period; and three from a longitudinal cohort in Fiji over a four-year period.FindingsWe found strong evidence of a decline in seroprevalence in both countries over a two-year period following first reported ZIKV transmission. In the cohort in Fiji, there was also a significant decline in antibody titres against ZIKV. However, the decline in seroprevalence was concentrated in adults, while high seroprevalence persisted in children.InterpretationThe observed patterns of long-term anti-ZIKV antibody levels following outbreaks in the Pacific could be an early indication of the dynamics of population immunity in Latin America. Given that ZIKV antibody levels can wane substantially over time, follow-up seroprevalence studies and prospective clinical trial designs in Latin America may need to be revised, and assumptions about the potential for ZIKV to re-emerge may need to be revisited.FundingPacific Funds, ANR, MRC, Wellcome, Royal Society.


mBio ◽  
2017 ◽  
Vol 8 (2) ◽  
Author(s):  
Douglas G. Widman ◽  
Ellen Young ◽  
Boyd L. Yount ◽  
Kenneth S. Plante ◽  
Emily N. Gallichotte ◽  
...  

ABSTRACT Zika virus (ZIKV), a mosquito-borne flavivirus discovered in 1947, has only recently caused large outbreaks and emerged as a significant human pathogen. In 2015, ZIKV was detected in Brazil, and the resulting epidemic has spread throughout the Western Hemisphere. Severe complications from ZIKV infection include neurological disorders such as Guillain-Barré syndrome in adults and a variety of fetal abnormalities, including microcephaly, blindness, placental insufficiency, and fetal demise. There is an urgent need for tools and reagents to study the pathogenesis of epidemic ZIKV and for testing vaccines and antivirals. Using a reverse genetics platform, we generated six ZIKV infectious clones and derivative viruses representing diverse temporal and geographic origins. These include three versions of MR766, the prototype 1947 strain (with and without a glycosylation site in the envelope protein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of the virus introduced to Brazil. In the course of synthesizing a clone of a circulating Brazilian strain, phylogenetic studies identified two distinct ZIKV clades in Brazil. We reconstructed viable clones of strains SPH2015 and BeH819015, representing ancestral members of each clade. We assessed recombinant virus replication, binding to monoclonal antibodies, and virulence in mice. This panel of molecular clones and recombinant virus isolates will enable targeted studies of viral determinants of pathogenesis, adaptation, and evolution, as well as the rational attenuation of contemporary outbreak strains to facilitate the design of vaccines and therapeutics. IMPORTANCE Viral emergence is a poorly understood process as evidenced by the sudden emergence of Zika virus in Latin America and the Caribbean. Malleable reagents that both predate and span an expanding epidemic are key to understanding the virologic determinants that regulate pathogenesis and transmission. We have generated representative cDNA molecular clones and recombinant viruses that span the known ZIKV family tree, including early Brazilian isolates. Recombinant viruses replicated efficiently in cell culture and were pathogenic in immunodeficient mice, providing a genetic platform for rational vaccine and therapeutic design. IMPORTANCE Viral emergence is a poorly understood process as evidenced by the sudden emergence of Zika virus in Latin America and the Caribbean. Malleable reagents that both predate and span an expanding epidemic are key to understanding the virologic determinants that regulate pathogenesis and transmission. We have generated representative cDNA molecular clones and recombinant viruses that span the known ZIKV family tree, including early Brazilian isolates. Recombinant viruses replicated efficiently in cell culture and were pathogenic in immunodeficient mice, providing a genetic platform for rational vaccine and therapeutic design.


BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e042869
Author(s):  
Joan K Morris ◽  
Helen Dolk ◽  
Pablo Durán ◽  
Ieda Maria Orioli

ObjectivesTo summarise the occurrence of congenital Zika syndrome (CZS) in Latin America and the Caribbean from 2015 to 2017 using two outcome measures derived from infectious disease surveillance reports and to assess the completeness of these reports.DesignSurveillance study.SettingPan American Health Organization (PAHO)/WHO epidemiology reports on confirmed and suspected Zika virus infection and cases of CZS.ParticipantsPopulations of 47 countries in the South and Central Americas, Mexico and the Caribbean.Primary and secondary outcome measuresThe number of CZS cases per 1000 births (using 2016–2017 births as a denominator) and the number of CZS cases per 1000 births in women with Zika virus infection during pregnancy.ResultsBy 4 January 2018, 548623 suspected and 239063 confirmed Zika virus infections had been reported to PAHO/WHO from 47 countries. In 25 countries, over 80% of infections were reported as suspected. There were 3617 confirmed CZS cases in 25 countries; 2952 (82%) had occurred in Brazil. The number of CZS cases per 1000 births varied considerably with Brazil and several Caribbean island communities (Puerto Rico, St Martin, Martinique, Guadeloupe and Grenada) having the highest CZS prevalence above 0.5 per 1000 births. Analysing the number of CZS cases per 1000 births in women infected with Zika virus during their pregnancy highlighted the inaccuracies of the data, with Venezuela likely to have had severe under-reporting of CZS.ConclusionsExpressing data on CZS in relation to total births, rather than as absolute numbers, better illustrates the burden of disease, providing that under-reporting of CZS is not too severe. Data on infections in pregnant women enable potential under-reporting of CZS to be identified. Both measures are recommended for future PAHO/WHO publications. Evidence of severe under-reporting of Zika virus infections and CZS makes interpretation of the data and comparisons between countries challenging.


Sign in / Sign up

Export Citation Format

Share Document